Baxiva a biotechnology startup developing next-generation glycoconjugate vaccines to combat bacterial infections.
Baxiva has raised $194K in total funding. The most recent round was Grant. The last funding was announced in February 2026.
Baxiva's investors include Venture Kick, CARB-X.
Baxiva is headquartered in Schlieren, Switzerland.
Baxiva a biotechnology startup developing next-generation glycoconjugate vaccines to combat bacterial infections.
Baxiva is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Baxiva — Funding & Investors." VCBacked, February 23, 2026, https://www.vcbacked.co/company/baxiva. Accessed July 20, 2026.
VCBacked. (2026). Baxiva — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/baxiva
{{cite web |title=Baxiva — Funding & Investors |url=https://www.vcbacked.co/company/baxiva |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated